From the academic bench to the forefront of global drug discovery
June 20, 2024
Voices of our journey
While working on my doctorate in clinical immunology, I encountered variants of the Chandler Loop model, used to study blood-material interactions. Could this be an assay applied to understand blood-drug interactions, aiming to get a holistic picture of the effects on blood and its cells? That was really the start, taking an existing idea and pushing it in a new direction says Sara Mangsbo, Professor and Co-founder.
A decade of achievements
- Expanded the business internationally, collaborating with clients in more than 20 countries.
- Continued to develop new assays and received industry recognition for our contributions to immunology and drug safety.
- Among the first to provide a non-animal technology to comprehensively assess immunotoxicity & immunopharmacology.
- Achieved Good Laboratory Practice (GLP) certification, enhancing the credibility and regulatory compliance of our immunoassay services.
Pioneering today
- Focus on providing ethical & animal-free methods in pharmaceutical research.
- Ensuring that all assay readouts meet the expectations outlined in the FDA guideline for immunotoxicology, supporting regulatory compliance and enhancing the reliability of safety assessments.
- Spreading awareness of ID.Flow’s strong correlation between assay results and human immune responses in the clinical setting.
As we look to the future, we’re excited about bringing you even more innovative solutions. Our commitment to quality and client satisfaction remains our top priority. Together, we are poised for great achievements and advancements.
Thank you for being an integral part of our journey.
Camilla Oldgren, CEO